Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AccuraGen, Adjunct, AEs, aforesaid, AgreementSM, Anderson, Aon, Apexigen, Appendix, Ariagen, ATM, bacteremia, Blair, Bloomington, breakthrough, Centre, Chem, Chugai, Circuit, collateralized, compliant, consecutive, Cui, curb, customary, Daniel, Decheng, downgrading, dramatic, Efung, embody, Encodia, Endogena, exploratory, fluid, forthcoming, franchise, Fujisawa, Fulphila, GP, haptoglobin, Hoosier, implicit, index, Indiana, infection, innate, instigating, intrusion, justified, MD, movement, Mylan, Nanjing, Nimble, Northern, Omniome, outbreak, owed, pandemic, peer, persistency, persistent, Pharmacy, preemptive, premise, prepaid, prophylactical, prophylactically, RDI, readjustment, readout, reiterate, renamed, republished, residual, rolling, ROU, run, Saint, Sandoz, Searle, SEED, Sequencing, shift, simplification, simulating, smooth, speed, SRA, strain, surfaced, Syntex, TEEWIN, therewith, timeline, Udenyca, unconstitutional, underwritten, undiscounted, unease, uniform, unincorporated, upheld, Ventana, widespread, William, WindMI, WindMIL, worsen, worst, Xiangmin, Zabrowski, Ziextenzo
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.2 Exhibit 2.2
- 4.3 Exhibit 4.3
- 4.15 Exhibit 4.15
- 4.20 Exhibit 4.20
- 4.21 Exhibit 4.21
- 4.22 Exhibit 4.22
- 4.23 Exhibit 4.23
- 4.24 Exhibit 4.24
- 4.25 Exhibit 4.25
- 8.1 Exhibit 8.1
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
- 15.2 Exhibit 15.2
- 15.3 Exhibit 15.3
- Download Excel data file
- View Excel data file
BYSI similar filings
Filing view
External links
Exhibit 4.24
Lan Huang, Ph.D. Chief Executive Officer BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 Tel: 646.305.6387 |
December 9, 2019
RE: | ANNUAL SALARY RAISE |
Ramon W. Mohanlal
Dear Ramon,
We are pleased to offer you an increase in your annual base salary from $300,000.00 to $430,000.00. In addition, we are increasing your annual bonus opportunity from 30% of annual salary to 45% of annual salary (otherwise subject to the same terms and conditions in your Employment Agreement (defined below). This change will be effective retroactive to July 1, 2019. On the next payroll date following the date of this letter, you will receive a payment reflecting the increased salary for the period of July 1, 2019, through December 31, 2019.
Except as expressly provided in this letter, your employment agreement with BeyondSpring Pharmaceuticals, Inc., dated as of April 1, 2016, as amended by that amendment dated as of November 10, 2016, (your “Employment Agreement”) shall remain in full force and effect.
Again, congratulations on your achievement and we wish you all the very best in the coming years. Please let me know if you have any questions regarding your new compensation package.
Sincerely,
/s/ Lan Huang | |
Lan Huang, Ph.D. | |
Agreed: | |
/s/ Ramon W. Mohanlal | |
Ramon W. Mohanlal |